Actively Recruiting
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Led by Jinling Hospital, China · Updated on 2025-12-11
450
Participants Needed
1
Research Sites
387 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.
CONDITIONS
Official Title
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed renal cell carcinoma
- No previous cancer treatment
- Agree to radical surgery
- Signed informed consent
- ECOG performance status of 0 or 1
- Willingness to follow the study protocol and procedures
You will not qualify if you...
- History of other cancers
- Prior antitumor therapy
- Known or suspected active autoimmune disease
- Unable to provide informed consent due to medical or psychiatric issues
- Uncontrolled heart symptoms or diseases
- Deemed unsuitable for the study by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
Nanjing, Jiangsu, China, 210000
Actively Recruiting
Research Team
L
Le Qe, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here